0%

est. 2Y upside i

HealthcareSeries A

Eyebot is an outcome-focused technology company on a mission to make vision care accessible to everyone, equally. Headquartered in Boston’s North End and backed by top investors and the National Science Foundation, their 90-second vision test kiosk is reshaping how vision care is delivered.

Rank

#2160

Sector

Healthtech

Est. Liquidity

~4Y

Data Quality

Data: Low

The equity opportunity at Eyebot is highly uncertain due to missing key financial data (revenue, valuation, growth rate).

Last updated: July 19, 2026

Bull (10%)0%

Unable to quantify due to missing financial data. Potential high upside if regulatory barriers are overcome and kiosk network expands rapidly.

Base (55%)0%

Unable to quantify. Likely moderate growth but overshadowed by regulatory risks and thin competitive moat.

Bear (35%)0%

Unable to quantify. Significant downside risk from regulatory enforcement (AOA complaints, FDA/FTC action) potentially leading to business disruption or failure.

Est. time to liquidity~4.0 years

Preference Stack Risk

moderate

Funding Intensity

0%

Total funding of $28M against an estimated valuation (if known) determines preference. Without valuation, preference risk cannot be precisely assessed.

Dilution Risk

low

Given $28M total funding and recent Series A (Aug 2025), runway likely covers 3-4 years, so no near-term dilution expected.

Secondary Liquidity

none

No secondary market data available; likely no liquidity for employees until a future round or exit.

Engineering — 3 roles

Compliance — 1 role

Operations — 1 role

View all 6 open roles at Eyebot →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Eyebot's data — designed to show you've done your homework.

  • 1

    “How does Eyebot plan to address the regulatory concerns raised by the AOA regarding FDA enforcement and FTC investigations?”

  • 2

    “What is the current unit economics of a kiosk (cost per unit, average prescription fee, utilization rate) and how do you expect these to evolve?”

  • 3

    “What is Eyebot's expected runway and dilution risk for employees over the next 2-3 years?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.